Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg; Mo, Fei; Chodak, Gerald W.; Sinner, Michael; Cella, David; Pienta, Kenneth J.

doi:10.1016/s0090-4295(97)00459-7

Cited by 617 publications

(456 citation statements)

References 21 publications

Supporting

Mentioning

402

Contrasting

Unclassified

Order By: Relevance

“…Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global QoL score. Higher scores reflect better QoL [28]. Internal consistency as measured by Cronbach's _ was at least 0.84 for all 5 subscales.…”

Section: Assessment Instrumentsmentioning

confidence: 89%

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Saini

Berruti

Cracco

et al. 2013

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Section: Assessment Instrumentsmentioning

confidence: 89%

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Saini

Berruti

Cracco

et al. 2013

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

“…": "Very discontent (1)", "Discontent (2)", "Slightly discontent (3)" or "Unanxious (4)". The Japanese version 6 of the Functional Assessment of Cancer Therapy-Prostate (FACT-P), 7 the validity of which has been verified, was used to evaluate QOL of the patients. Hot flashes and QOL were evaluated according to the self-administered system.…”

Section: Assessmentsmentioning

confidence: 99%

Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer

Sakai

Igawa

Tsurusaki

et al. 2009

Urology

View full text Add to dashboard Cite

Objectives:We conducted a prospective, randomized study to investigate hot flashes and quality of life (QOL) during combined androgen blockade (CAB) therapy using steroidal or nonsteroidal antiandrogens. Methods:A total of 151 patients with prostate cancer, enrolled into this study between May 2001and June 2003, were randomized to receive CAB therapy using an LHRH agonist (leuprorelin) combined with a steroidal antiandrogen (chlormadinone) or a nonsteroidal antiandrogen (bicalutamide). The incidence of, frequency of, and distress due to hot flashes were evaluated with a self-entry questionnaire over 2 years. General and disease-specific QOL outcomes were also measured with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.Results: Data were available for analysis on 124 patients. Although the incidence of hot flashes largely tended to be higher in the bicalutamide group than in the chlormadinone group, no significant difference was noted in the cumulative incidence of hot flashes at 2 years. The median frequency of hot flashes per day was 1.3 and 2.2 for warmth/flushing (P = 0.16) and 1.0 and 3.6 for sweating (P = 0.021) in the chlormadinone and bicalutamide groups, respectively. Patients in the chlormadinone group were significantly less likely to be distressed due to warmth/flushing 4 (OR 0.47, P < 0.001) and sweating (OR 0.61, P = 0.01) than those in the bicalutamide group.The time course of FACT-P scores showed no inter-group differences. Conclusions:Our results suggest that CAB using a steroidal antiandrogen such as chlormadinone may induce fewer and less distressing hot flashes than CAB with bicalutamide.

show abstract

“…5,15 Previous studies have used the FACT-P to evaluate QoL in patients with prostate cancer undergoing external beam radiotherapy, 16 brachytherapy, 16,17 surgery, 16 cryosurgery, 18,19 chemotherapy 20 and treatment with an epidermal growth factor receptor inhibitor. 21 These studies have reported significant changes in health-related QoL in response to the various anti-cancer treatments.…”

Section: Quality Of Life In Prostate Cancermentioning

confidence: 99%

Measuring the individual quality of life of patients with prostate cancer

Stone

Matar

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate cancer can have diverse effects on patients' quality of life (QoL). Standard QoL questionnaires do not address all of the concerns expressed by such patients. The primary purpose of this study was to identify those issues with the greatest influence on the QoL of patients with prostate cancer. A secondary aim was to compare the performance of the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) semi-structured interview with the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P). A mixed population of patients with prostate cancer (including those with localized and metastatic disease) completed the SEIQoL-DW and the FACT-P. The SEIQoL-DW was satisfactorily completed by 180 patients, including 93 patients with metastatic disease. Patients identified 144 separate QoL concerns, and these were then independently grouped by three of the authors into 13 distinct themes. The most frequently identified themes were 'leisure and hobbies', 'family' and 'health'. The themes that patients considered to be the most important were 'partner/spouse', 'family' and 'health'. Patients were most satisfied with their QoL in the domains of 'family', 'partner/spouse' and 'friends'. They were least satisfied with 'sexuality', 'mobility' and 'psychological factors'. Patients with metastatic disease rated their QoL significantly (Po0.0001) lower than other patients using the FACT-P, but not using the SEIQoL-DW (P ¼ 0.07). Patients with prostate cancer identified numerous QoL concerns that are not included (or are underrepresented) in standard health-related QoL questionnaires such as the FACT-P. Health-related QoL questionnaires may underestimate the QoL of patients with metastatic disease.

show abstract

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Cited by 617 publications

References 21 publications

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy

Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer

Measuring the individual quality of life of patients with prostate cancer

Contact Info

Product

Resources

About